Ceftolozane/tazobactam heteroresistance in cystic fibrosis-related Pseudomonas aeruginosa infections.
Marguerite L MonogueJames M SandersChristine A PybusJiwoong KimXiaowei ZhanAndrew E ClarkDavid E GreenbergPublished in: JAC-antimicrobial resistance (2023)
isolates in this work, and approximately a quarter of these populations contained isolates with ceftolozane/tazobactam susceptibiilty interpretations different from what was reported clinically, supporting concerns surrounding the utility of traditional susceptibility testing methodology in the setting of CF specimens. Genome sequencing of isolates with acquired MHR to ceftolozane/tazobactam revealed variants of unknown significance. Future work will be centred on determining the significance of these mutations to better understand these data in clinical context.
Keyphrases
- gram negative
- cystic fibrosis
- pseudomonas aeruginosa
- genetic diversity
- multidrug resistant
- single cell
- lung function
- acinetobacter baumannii
- biofilm formation
- drug resistant
- electronic health record
- staphylococcus aureus
- dna methylation
- current status
- genome wide
- machine learning
- escherichia coli
- artificial intelligence
- deep learning